Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EPS (Basic): 2019-2025

Historic EPS (Basic) for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$1.27.

  • Avidity Biosciences' EPS (Basic) fell 95.38% to -$1.27 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.19, marking a year-over-year decrease of 44.98%. This contributed to the annual value of -$2.89 for FY2024, which is 0.69% up from last year.
  • Avidity Biosciences' EPS (Basic) amounted to -$1.27 in Q3 2025, which was down 4.96% from -$1.21 recorded in Q2 2025.
  • Avidity Biosciences' 5-year EPS (Basic) high stood at -$0.64 for Q1 2021, and its period low was -$1.27 during Q3 2025.
  • For the 3-year period, Avidity Biosciences' EPS (Basic) averaged around -$0.84, with its median value being -$0.79 (2024).
  • The largest annual percentage gain for Avidity Biosciences' EPS (Basic) in the last 5 years was 70.09% (2021), contrasted with its biggest fall of 119.35% (2021).
  • Over the past 5 years, Avidity Biosciences' EPS (Basic) (Quarterly) stood at -$0.84 in 2021, then declined by 5.95% to -$0.89 in 2022, then increased by 10.11% to -$0.80 in 2023, then decreased by 1.25% to -$0.81 in 2024, then tumbled by 95.38% to -$1.27 in 2025.
  • Its EPS (Basic) stands at -$1.27 for Q3 2025, versus -$1.21 for Q2 2025 and -$0.90 for Q1 2025.